RVTY REVVITY, INC.
Laboratory Analytical Instruments · NYSE · SEC CIK 31791 · Fiscal year ends 12/29
Financial factors as of 2026-10-04 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.6%
TTM net income YoY6.6%
TTM EPS YoY12.6%
Revenue 3-yr CAGR1.7%
Net income 3-yr CAGR-30.1%
Margins
Gross margin—
Operating margin12.6%
Net margin8.6%
FCF margin20.1%
EBITDA margin20.9%
Returns
ROE3.5%
ROA2.1%
ROIC (approx.)3.5%
Asset turnover0.25x
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.36x
Current ratio2.65x
Interest coverage4.04x
Cash quality & payout
Operating cash flow / net income2.59x
Accruals ratio-3.4%
Payout ratio12.4%
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-28 | FY20242024-12-29 | FY20232023-12-31 | FY20222023-01-01 | FY20212022-01-02 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B |
| Gross profit | — | — | — | $1.99B | $2.43B |
| R&D expense | $215.84M | $196.84M | $216.58M | $221.62M | $200.34M |
| SG&A expense | $991.89M | $994.07M | $1.02B | $1.03B | $975.19M |
| Operating income | $356.63M | $346.74M | $300.56M | $742.70M | $1.26B |
| Interest expense | $92.19M | $96.28M | $98.81M | $103.95M | — |
| Pretax income | $268.28M | $316.13M | $182.98M | $651.84M | $1.20B |
| Income tax | $28.39M | $33.05M | $3.47M | $139.16M | $314.15M |
| Net income | $241.20M | $270.38M | $693.09M | $569.18M | $943.16M |
| EBITDA | $761.98M | $774.59M | $732.33M | $1.17B | $1.57B |
| EPS (basic) | 2.07 | 2.21 | 5.56 | 4.51 | 8.12 |
| EPS (diluted) | 2.07 | 2.20 | 5.55 | 4.50 | 8.08 |
| Dividends declared per share | 0.28 | 0.28 | 0.28 | 0.28 | — |
| Weighted avg. shares (diluted) | 116.59M | 122.82M | 124.81M | 126.43M | 116.67M |
| Balance sheet | |||||
| Cash & equivalents | $919.86M | $1.16B | $913.16M | $470.75M | $619.34M |
| Short-term investments | — | $0 | $689.92M | $0 | — |
| Receivables | $744.67M | $632.40M | $632.81M | $612.78M | $707.94M |
| Inventory | $379.50M | $367.59M | $428.06M | $405.46M | $425.89M |
| Current assets | $2.24B | $2.35B | $3.00B | $3.29B | $2.44B |
| PP&E, net | $479.25M | $482.22M | $509.65M | $482.95M | $485.53M |
| Goodwill | $6.61B | $6.46B | $6.53B | $6.48B | $6.63B |
| Intangibles | $2.35B | $2.64B | $3.02B | $3.38B | $3.82B |
| Total assets | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B |
| Current liabilities | $1.33B | $653.10M | $1.45B | $1.54B | $1.21B |
| Short-term debt | $588.83M | $242,000 | $721.87M | $470.93M | $4.24M |
| Long-term debt | $2.63B | $3.15B | $3.18B | $3.92B | $4.98B |
| Total debt | $3.22B | $3.15B | $3.90B | $4.39B | $4.98B |
| Total liabilities | $4.92B | $4.73B | $5.69B | $6.75B | $7.86B |
| Shareholders' equity | $7.25B | $7.67B | $7.87B | $7.38B | $7.14B |
| Net debt | $2.30B | $1.99B | $2.99B | $3.92B | $4.36B |
| Shares outstanding | 112.28M | 120.65M | 123.43M | 126.30M | 126.24M |
| Cash flow statement | |||||
| Operating cash flow | $582.93M | $628.30M | $91.27M | $679.81M | $1.41B |
| Capital expenditure | $73.52M | $86.65M | $81.37M | $85.63M | $86.02M |
| Free cash flow | $509.41M | $541.65M | $9.90M | $594.18M | $1.32B |
| Investing cash flow | -$17.35M | $776.16M | $1.31B | -$132.85M | -$4.11B |
| Financing cash flow | -$857.52M | -$1.13B | -$947.12M | -$661.80M | $2.94B |
| Depreciation & amortization | $405.34M | $427.85M | $431.77M | $427.00M | $311.44M |
| Stock-based compensation | $22.85M | $37.81M | $41.41M | $51.52M | $29.68M |
| Dividends paid | $32.80M | $34.45M | $34.97M | $35.34M | $32.37M |
| Share buybacks | $820.82M | $369.58M | $388.88M | $80.64M | $73.07M |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.